You are here

Article Text

Article menu
Download PDFPDF
Letter
Protective effect of A at position –168 in the type III promoter of the MHCIITA gene in systemic lupus erythematosus
  1. Hiroshi Okamoto,
  2. Hirotaka Kaneko,
  3. Chihiro Terai,
  4. Naoyuki Kamatani
  1. Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
  1. Correspondence to:
    Hiroshi Okamoto
    Institute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawada-cho, Shinjuku, Tokyo 162-0054, Japan; hokamoto{at}ior.twmu.ac.jp

https://doi.org/10.1136/ard.2006.066142

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The MHC class II transactivator (MHCIITA) gene was originally identified as a defective gene associated with bare lymphocyte syndrome, a severe combined immunodeficiency syndrome. Evidence indicates that MHCIITA is a master switch of antigen presentation in antigen-presenting cells.1 A recent paper describes how a –168A ->G polymorphism in the type III promoter of the MHC2TA gene was associated with increased susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction, as well as lower expression of MHC2TA after stimulation of leukocytes with interferon-gamma (IFN-γ).2,3 However, similar replicated studies in two other European populations did not find this association.4,5

    Systemic lupus erythematosus (SLE) …

    View Full Text

    Footnotes

    • Competing interests: None declared.